Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have received an average rating of "Moderate Buy" from the seven brokerages that are currently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $8.50.

Several analysts have recently issued reports on ANRO shares. Wedbush reiterated a "neutral" rating and issued a $4.00 target price on shares of Alto Neuroscience in a research report on Thursday, May 15th. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Alto Neuroscience in a research report on Thursday, June 26th.

Alto Neuroscience Price Performance

Shares of NYSE:ANRO remained flat at $3.08 during midday trading on Thursday. 117,445 shares of the stock were exchanged, compared to its average volume of 282,530. The firm has a market capitalization of $83.38 million, a price-to-earnings ratio of -1.32 and a beta of 1.65. Alto Neuroscience has a 1 year low of $1.60 and a 1 year high of $15.04. The firm has a fifty day moving average price of $2.58 and a two-hundred day moving average price of $2.90. The company has a debt-to-equity ratio of 0.15, a current ratio of 22.53 and a quick ratio of 22.53.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.06. Sell-side analysts anticipate that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Personalized Indexing Management LLC acquired a new position in Alto Neuroscience in the 2nd quarter valued at about $33,000. SCS Capital Management LLC acquired a new position in Alto Neuroscience in the 1st quarter valued at about $144,000. AQR Capital Management LLC purchased a new stake in shares of Alto Neuroscience in the 1st quarter valued at approximately $52,000. AWM Investment Company Inc. raised its stake in shares of Alto Neuroscience by 31.1% in the 1st quarter. AWM Investment Company Inc. now owns 901,984 shares of the company's stock valued at $1,948,000 after acquiring an additional 214,153 shares during the period. Finally, Armistice Capital LLC raised its stake in shares of Alto Neuroscience by 146.2% in the 1st quarter. Armistice Capital LLC now owns 1,600,000 shares of the company's stock valued at $3,456,000 after acquiring an additional 950,000 shares during the period.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.